LWM
SRNE

Lenox Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Lenox Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$0 Buy
+12
New +$46 ﹤0.01% 813

Other funds holding SRNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Lenox Wealth Management's SRNE Position: Q2 2020 in Review

Lenox Wealth Management opened a new position in Sorrento Therapeutics, Inc. (SRNE) in Q2 2020: 12 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #813 among its holdings.

186 funds tracked by Wall St. Rank hold SRNE as of Q2 2020.

  • Lenox Wealth Management held 12 shares of Sorrento Therapeutics, Inc. worth $0 as of Q2 2020.
  • Sorrento Therapeutics, Inc. was a new Lenox Wealth Management position in Q2 2020.
  • Sorrento Therapeutics, Inc. made up ﹤0.01% of Lenox Wealth Management's portfolio in Q2 2020, its #813 holding.
  • 186 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2020.

Based on Lenox Wealth Management's 13F filing for Q2 2020, filed 28 Jul 2020.